Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations

Authors :: Holm Bussler
Maria Scrivens
Leslie Balch
Janaki Veeraraghavan
John E. Leonard
Ernest S. Smith
Ekaterina Klimatcheva
Sebold Torno
Siwen Hu-Lieskovan
Terrence L. Fisher
Alan Howell
Laurie A. Winter
Crystal Mallow
Elizabeth E. Evans
Antoni Ribas
Maurice Zauderer
Renee Kirk
Mark Paris
Alan S. Jonason
Christine Reilly
Source :: Journal for Immunotherapy of Cancer
Publisher :: Springer Nature
Abstract: Meeting abstracts Semaphorin 4D (SEMA4D, CD100) and its receptor plexin-B1 are broadly expressed in cancer and expression correlates with invasive disease in several human tumors. SEMA4D normally functions to regulate the motility and differentiation of multiple cell types, including those of the

Full Text Access

Tools